PACE-CME

DKD and CV risk: What is the potential of targeting GLP-1?

DKD and CV risk What is the potential of targeting GLP
RestartResume
10' education - June 16, 2020 - Prof. Erik Stroes, MD
  • Overview

    Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.

  • Educational information

    This lecture by prof. Erik Stroes was part of the EBAC-accredited symposium "Cardiorenal cross-talk in diabetes: The preventive challenge in DKD for GLP-1RA" held during ERA EDTA Virtual Congress 2020.

  • Faculty

    Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

    Click here for the meeting report

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free